20 articles
A landmark JCI review maps the expanding pharmacological arsenal for MASH, from GLP-1 agonists to triple receptor therapies and precision medicine.
A real-world study of 15,000+ patients finds tirzepatide outperforms both semaglutide and liraglutide in preventing major cardiac events.
A systematic review of 38 trials finds tirzepatide cuts HbA1c nearly 3x more than lixisenatide with similar GI side effect rates.
Landmark CKD trials enrolled mostly overweight patients — new evidence questions whether SGLT2 inhibitors work for lean, non-diabetic individuals.
New study reveals how the diabetes drug dapagliflozin dramatically alters fat metabolism and kidney function through previously unknown pathways.
Combined mitochondrial therapy restored muscle function and reduced fatigue in mouse model of Gulf War Illness.
Comprehensive therapy combining Western medicine, traditional Chinese medicine, and lifestyle changes reversed diabetes in majority of patients.
A landmark RCT shows finerenone reduces eGFR decline and kidney-cardiovascular events in CKD patients without diabetes.
A landmark Lancet review reveals GLP-1 receptor agonists protect the heart, kidneys, liver, and brain — reshaping how we think about metabolic medicine.
HDM1002, an oral GLP-1 receptor agonist, achieved significant weight loss with manageable side effects in overweight Chinese adults.
FDA approval of the first T1D delay drug nearly doubled islet autoantibody testing, but critical gaps remain in screening healthy children.
Phase 3 trial shows once-weekly mazdutide injections led to significant weight loss with minimal side effects in overweight Chinese adults.
New analysis reveals that comparing weight changes between diabetes medications requires more sophisticated research methods.
Updated review of anti-obesity medications in MASLD finds GLP-1 agonists reduce steatosis and fibrosis, while newer dual/triple agonists show even greater metabolic promise.
Advanced incretin-based therapies show potential for major weight loss while protecting heart, kidney, liver, and brain health.
Novel obesity drug targeting two pathways simultaneously shows unprecedented weight loss results in recent clinical studies.
Weekly tirzepatide injections led to up to 22% weight loss in Japanese participants, with 96-100% achieving clinically significant results.
A major Cochrane network meta-analysis protocol will rank all insulin regimens by efficacy and safety for adults with type 1 diabetes.
A systematic review of 8 studies finds tirzepatide significantly reduces hsCRP and IL-6 across all doses and populations.
A comprehensive 2025 review framework matches GLP-1 agonists, tirzepatide, and other AOMs to specific obesity phenotypes, complications, and life stages.
